Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan

Autosomal dominant polycystic kidney disease (ADPKD) is a cause of end-stage kidney disease (ESKD). The vasopressin V2-receptor antagonist tolvaptan has been shown within randomized clinical trials to slow down decline of kidney function in patients with ADPKD at risk of rapid progression. We perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkekas, Eleftherios, Tang, Tsz Yau Tiffany, Green, Alan, Davidson, Han, Fraser, Rachel, Sayer, John A., Srivastava, Shalabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Nephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479563/
https://www.ncbi.nlm.nih.gov/pubmed/37674994
http://dx.doi.org/10.3389/fneph.2022.984165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479563/
https://www.ncbi.nlm.nih.gov/pubmed/37674994
http://dx.doi.org/10.3389/fneph.2022.984165

Ejemplares similares